ProQR Therapeutics N.V. (PRQR)
NASDAQ: PRQR · Real-Time Price · USD
1.310
-0.070 (-5.07%)
At close: Nov 10, 2026, 4:00 PM EST
1.352
+0.042 (3.21%)
After-hours: Nov 10, 2026, 7:30 PM EST
ProQR Therapeutics Revenue
ProQR Therapeutics had revenue of 8.76M EUR in the quarter ending June 30, 2026, with 120.35% growth. This brings the company's total for the last twelve months to 18.42M, up 7.49% year-over-year. In the year 2025, ProQR Therapeutics had annual revenue of 16.35M, down -16.36%. That makes ProQR Therapeutics the 33,549th largest company in the world by revenue and 4,393rd in the United States.
Revenue (ttm)
18.42M EUR
Revenue Growth
+7.49%
P/S Ratio
8.88
Revenue / Employee
98,730 EUR
Employees
187
Market Cap
184.87M USD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 16.35M | -3.20M | -16.36% |
| Dec 31, 2024 | 19.55M | 10.02M | 105.20% |
| Dec 31, 2023 | 9.53M | 5.17M | 118.51% |
| Dec 31, 2022 | 4.36M | 1.98M | 83.31% |
| Dec 31, 2021 | 2.38M | -7.07M | -74.84% |
| Dec 31, 2020 | 9.45M | 7.52M | 388.98% |
| Dec 31, 2019 | 1.93M | -3.83M | -66.45% |
| Dec 31, 2018 | 5.76M | 4.27M | 285.35% |
| Dec 31, 2017 | 1.50M | -333.00K | -18.22% |
| Dec 31, 2016 | 1.83M | -1.41M | -43.49% |
| Dec 31, 2015 | 3.24M | 2.92M | 933.55% |
| Dec 31, 2014 | 313.00K | 197.00K | 169.83% |
| Dec 31, 2013 | 116.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Protalix BioTherapeutics | 84.69M |
| Compugen | 75.93M |
| Alpha Cognition | 15.26M |
| MediWound | 11.86M |
| Pyxis Oncology | 11.04M |
| Upstream Bio | 2.87M |
| Sol-Gel Technologies | 1.80M |
| Korro Bio | 1.29M |
PRQR News
- 13 days ago - ProQR to Present Clinical and Preclinical Progress from AX-0810 and AX-0811 at Upcoming Conferences - GlobeNewsWire
- 27 days ago - ProQR Therapeutics management to meet with Oppenheimer - TheFly
- 4 weeks ago - ProQR Therapeutics management to meet with Oppenheimer - TheFly
- 5 weeks ago - ProQR price target lowered to $8 from $12 at H.C. Wainwright - TheFly
- 5 weeks ago - ProQR Therapeutics Transcript: Investor update - Transcripts
- 5 weeks ago - ProQR Therapeutics Slides: Investor update - Filings
- 5 weeks ago - ProQR Therapeutics Press release: Investor update - Filings
- 6 weeks ago - ProQR Announces Appointment of Chris Hart as Chief Data and AI Officer and Thomas Wolf to join the Board of Directors as Strategic AI Advisor - GlobeNewsWire